ecgm mv medium Search Results


endothelial cell growth medium ecgm  (PromoCell)
99
PromoCell endothelial cell growth medium ecgm
Endothelial Cell Growth Medium Ecgm, supplied by PromoCell, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/endothelial cell growth medium ecgm/product/PromoCell
Average 99 stars, based on 1 article reviews
endothelial cell growth medium ecgm - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
endothelial cell growth medium mv  (PromoCell)
97
PromoCell endothelial cell growth medium mv
Passage of ranibizumab through the NDN or SHN did not change its typical characteristics. After incubation of VEGF-A 165 with ( A ) untreated ranibizumab or ( B ) ranibizumab repeatedly passed through a needle, free growth factor was determined by ELISA. Data from independent experiments were pooled and analyzed as described in Material and Methods, and are shown as scatter plots with means ± standard deviations. *p<0.05, **p<0.01, ***p<0.001, ****) p<0.0001; only statistically significant differences are shown. All measured concentrations of free VEGF-A were very low. ( C – F ) Confluent monolayers of retinal <t>endothelial</t> cells (iBREC) were exposed to vehicle (n=6), VEGF-A 165 (n=8), the growth factor plus ( C and F ) untreated (n=8), ( D and F ) SHN-treated (n=12) or ( E and F ) NDN-treated (n=11) ranibizumab for three days and the cell index was measured continuously. Cell index values were normalized and analyzed as described in Material and Methods. Means ± standard deviations are shown in ( C – E ), means only in ( F ). Ranibizumab efficiently prevented VEGF-A 165 -induced decline of cell index values which was not changed by its passage either through a SHN or the NDN.
Endothelial Cell Growth Medium Mv, supplied by PromoCell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/endothelial cell growth medium mv/product/PromoCell
Average 97 stars, based on 1 article reviews
endothelial cell growth medium mv - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier
ecgm 2 medium  (PromoCell)
96
PromoCell ecgm 2 medium
Passage of ranibizumab through the NDN or SHN did not change its typical characteristics. After incubation of VEGF-A 165 with ( A ) untreated ranibizumab or ( B ) ranibizumab repeatedly passed through a needle, free growth factor was determined by ELISA. Data from independent experiments were pooled and analyzed as described in Material and Methods, and are shown as scatter plots with means ± standard deviations. *p<0.05, **p<0.01, ***p<0.001, ****) p<0.0001; only statistically significant differences are shown. All measured concentrations of free VEGF-A were very low. ( C – F ) Confluent monolayers of retinal <t>endothelial</t> cells (iBREC) were exposed to vehicle (n=6), VEGF-A 165 (n=8), the growth factor plus ( C and F ) untreated (n=8), ( D and F ) SHN-treated (n=12) or ( E and F ) NDN-treated (n=11) ranibizumab for three days and the cell index was measured continuously. Cell index values were normalized and analyzed as described in Material and Methods. Means ± standard deviations are shown in ( C – E ), means only in ( F ). Ranibizumab efficiently prevented VEGF-A 165 -induced decline of cell index values which was not changed by its passage either through a SHN or the NDN.
Ecgm 2 Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ecgm 2 medium/product/PromoCell
Average 96 stars, based on 1 article reviews
ecgm 2 medium - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
egm-2 mv microvascular endothelial cell growth medium-2 bulletkit  (Lonza)
90
Lonza egm-2 mv microvascular endothelial cell growth medium-2 bulletkit
Passage of ranibizumab through the NDN or SHN did not change its typical characteristics. After incubation of VEGF-A 165 with ( A ) untreated ranibizumab or ( B ) ranibizumab repeatedly passed through a needle, free growth factor was determined by ELISA. Data from independent experiments were pooled and analyzed as described in Material and Methods, and are shown as scatter plots with means ± standard deviations. *p<0.05, **p<0.01, ***p<0.001, ****) p<0.0001; only statistically significant differences are shown. All measured concentrations of free VEGF-A were very low. ( C – F ) Confluent monolayers of retinal <t>endothelial</t> cells (iBREC) were exposed to vehicle (n=6), VEGF-A 165 (n=8), the growth factor plus ( C and F ) untreated (n=8), ( D and F ) SHN-treated (n=12) or ( E and F ) NDN-treated (n=11) ranibizumab for three days and the cell index was measured continuously. Cell index values were normalized and analyzed as described in Material and Methods. Means ± standard deviations are shown in ( C – E ), means only in ( F ). Ranibizumab efficiently prevented VEGF-A 165 -induced decline of cell index values which was not changed by its passage either through a SHN or the NDN.
Egm 2 Mv Microvascular Endothelial Cell Growth Medium 2 Bulletkit, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/egm-2 mv microvascular endothelial cell growth medium-2 bulletkit/product/Lonza
Average 90 stars, based on 1 article reviews
egm-2 mv microvascular endothelial cell growth medium-2 bulletkit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
basal medium mv  (PromoCell)
96
PromoCell basal medium mv
Passage of ranibizumab through the NDN or SHN did not change its typical characteristics. After incubation of VEGF-A 165 with ( A ) untreated ranibizumab or ( B ) ranibizumab repeatedly passed through a needle, free growth factor was determined by ELISA. Data from independent experiments were pooled and analyzed as described in Material and Methods, and are shown as scatter plots with means ± standard deviations. *p<0.05, **p<0.01, ***p<0.001, ****) p<0.0001; only statistically significant differences are shown. All measured concentrations of free VEGF-A were very low. ( C – F ) Confluent monolayers of retinal <t>endothelial</t> cells (iBREC) were exposed to vehicle (n=6), VEGF-A 165 (n=8), the growth factor plus ( C and F ) untreated (n=8), ( D and F ) SHN-treated (n=12) or ( E and F ) NDN-treated (n=11) ranibizumab for three days and the cell index was measured continuously. Cell index values were normalized and analyzed as described in Material and Methods. Means ± standard deviations are shown in ( C – E ), means only in ( F ). Ranibizumab efficiently prevented VEGF-A 165 -induced decline of cell index values which was not changed by its passage either through a SHN or the NDN.
Basal Medium Mv, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/basal medium mv/product/PromoCell
Average 96 stars, based on 1 article reviews
basal medium mv - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
ecgm  (PromoCell)
96
PromoCell ecgm
Passage of ranibizumab through the NDN or SHN did not change its typical characteristics. After incubation of VEGF-A 165 with ( A ) untreated ranibizumab or ( B ) ranibizumab repeatedly passed through a needle, free growth factor was determined by ELISA. Data from independent experiments were pooled and analyzed as described in Material and Methods, and are shown as scatter plots with means ± standard deviations. *p<0.05, **p<0.01, ***p<0.001, ****) p<0.0001; only statistically significant differences are shown. All measured concentrations of free VEGF-A were very low. ( C – F ) Confluent monolayers of retinal <t>endothelial</t> cells (iBREC) were exposed to vehicle (n=6), VEGF-A 165 (n=8), the growth factor plus ( C and F ) untreated (n=8), ( D and F ) SHN-treated (n=12) or ( E and F ) NDN-treated (n=11) ranibizumab for three days and the cell index was measured continuously. Cell index values were normalized and analyzed as described in Material and Methods. Means ± standard deviations are shown in ( C – E ), means only in ( F ). Ranibizumab efficiently prevented VEGF-A 165 -induced decline of cell index values which was not changed by its passage either through a SHN or the NDN.
Ecgm, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ecgm/product/PromoCell
Average 96 stars, based on 1 article reviews
ecgm - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
microvascular endothelial cell growth medium-2 (egm-2mv)  (Lonza)
90
Lonza microvascular endothelial cell growth medium-2 (egm-2mv)
Passage of ranibizumab through the NDN or SHN did not change its typical characteristics. After incubation of VEGF-A 165 with ( A ) untreated ranibizumab or ( B ) ranibizumab repeatedly passed through a needle, free growth factor was determined by ELISA. Data from independent experiments were pooled and analyzed as described in Material and Methods, and are shown as scatter plots with means ± standard deviations. *p<0.05, **p<0.01, ***p<0.001, ****) p<0.0001; only statistically significant differences are shown. All measured concentrations of free VEGF-A were very low. ( C – F ) Confluent monolayers of retinal <t>endothelial</t> cells (iBREC) were exposed to vehicle (n=6), VEGF-A 165 (n=8), the growth factor plus ( C and F ) untreated (n=8), ( D and F ) SHN-treated (n=12) or ( E and F ) NDN-treated (n=11) ranibizumab for three days and the cell index was measured continuously. Cell index values were normalized and analyzed as described in Material and Methods. Means ± standard deviations are shown in ( C – E ), means only in ( F ). Ranibizumab efficiently prevented VEGF-A 165 -induced decline of cell index values which was not changed by its passage either through a SHN or the NDN.
Microvascular Endothelial Cell Growth Medium 2 (Egm 2mv), supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/microvascular endothelial cell growth medium-2 (egm-2mv)/product/Lonza
Average 90 stars, based on 1 article reviews
microvascular endothelial cell growth medium-2 (egm-2mv) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
endothelial cell growth medium mv 2 media  (PromoCell)
98
PromoCell endothelial cell growth medium mv 2 media
Passage of ranibizumab through the NDN or SHN did not change its typical characteristics. After incubation of VEGF-A 165 with ( A ) untreated ranibizumab or ( B ) ranibizumab repeatedly passed through a needle, free growth factor was determined by ELISA. Data from independent experiments were pooled and analyzed as described in Material and Methods, and are shown as scatter plots with means ± standard deviations. *p<0.05, **p<0.01, ***p<0.001, ****) p<0.0001; only statistically significant differences are shown. All measured concentrations of free VEGF-A were very low. ( C – F ) Confluent monolayers of retinal <t>endothelial</t> cells (iBREC) were exposed to vehicle (n=6), VEGF-A 165 (n=8), the growth factor plus ( C and F ) untreated (n=8), ( D and F ) SHN-treated (n=12) or ( E and F ) NDN-treated (n=11) ranibizumab for three days and the cell index was measured continuously. Cell index values were normalized and analyzed as described in Material and Methods. Means ± standard deviations are shown in ( C – E ), means only in ( F ). Ranibizumab efficiently prevented VEGF-A 165 -induced decline of cell index values which was not changed by its passage either through a SHN or the NDN.
Endothelial Cell Growth Medium Mv 2 Media, supplied by PromoCell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/endothelial cell growth medium mv 2 media/product/PromoCell
Average 98 stars, based on 1 article reviews
endothelial cell growth medium mv 2 media - by Bioz Stars, 2026-03
98/100 stars
  Buy from Supplier
ecgm modecgm medium  (PromoCell)
96
PromoCell ecgm modecgm medium
Passage of ranibizumab through the NDN or SHN did not change its typical characteristics. After incubation of VEGF-A 165 with ( A ) untreated ranibizumab or ( B ) ranibizumab repeatedly passed through a needle, free growth factor was determined by ELISA. Data from independent experiments were pooled and analyzed as described in Material and Methods, and are shown as scatter plots with means ± standard deviations. *p<0.05, **p<0.01, ***p<0.001, ****) p<0.0001; only statistically significant differences are shown. All measured concentrations of free VEGF-A were very low. ( C – F ) Confluent monolayers of retinal <t>endothelial</t> cells (iBREC) were exposed to vehicle (n=6), VEGF-A 165 (n=8), the growth factor plus ( C and F ) untreated (n=8), ( D and F ) SHN-treated (n=12) or ( E and F ) NDN-treated (n=11) ranibizumab for three days and the cell index was measured continuously. Cell index values were normalized and analyzed as described in Material and Methods. Means ± standard deviations are shown in ( C – E ), means only in ( F ). Ranibizumab efficiently prevented VEGF-A 165 -induced decline of cell index values which was not changed by its passage either through a SHN or the NDN.
Ecgm Modecgm Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ecgm modecgm medium/product/PromoCell
Average 96 stars, based on 1 article reviews
ecgm modecgm medium - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
ec growth medium ecgm  (PromoCell)
96
PromoCell ec growth medium ecgm
Passage of ranibizumab through the NDN or SHN did not change its typical characteristics. After incubation of VEGF-A 165 with ( A ) untreated ranibizumab or ( B ) ranibizumab repeatedly passed through a needle, free growth factor was determined by ELISA. Data from independent experiments were pooled and analyzed as described in Material and Methods, and are shown as scatter plots with means ± standard deviations. *p<0.05, **p<0.01, ***p<0.001, ****) p<0.0001; only statistically significant differences are shown. All measured concentrations of free VEGF-A were very low. ( C – F ) Confluent monolayers of retinal <t>endothelial</t> cells (iBREC) were exposed to vehicle (n=6), VEGF-A 165 (n=8), the growth factor plus ( C and F ) untreated (n=8), ( D and F ) SHN-treated (n=12) or ( E and F ) NDN-treated (n=11) ranibizumab for three days and the cell index was measured continuously. Cell index values were normalized and analyzed as described in Material and Methods. Means ± standard deviations are shown in ( C – E ), means only in ( F ). Ranibizumab efficiently prevented VEGF-A 165 -induced decline of cell index values which was not changed by its passage either through a SHN or the NDN.
Ec Growth Medium Ecgm, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ec growth medium ecgm/product/PromoCell
Average 96 stars, based on 1 article reviews
ec growth medium ecgm - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
ecgm mv  (PromoCell)
96
PromoCell ecgm mv
Passage of ranibizumab through the NDN or SHN did not change its typical characteristics. After incubation of VEGF-A 165 with ( A ) untreated ranibizumab or ( B ) ranibizumab repeatedly passed through a needle, free growth factor was determined by ELISA. Data from independent experiments were pooled and analyzed as described in Material and Methods, and are shown as scatter plots with means ± standard deviations. *p<0.05, **p<0.01, ***p<0.001, ****) p<0.0001; only statistically significant differences are shown. All measured concentrations of free VEGF-A were very low. ( C – F ) Confluent monolayers of retinal <t>endothelial</t> cells (iBREC) were exposed to vehicle (n=6), VEGF-A 165 (n=8), the growth factor plus ( C and F ) untreated (n=8), ( D and F ) SHN-treated (n=12) or ( E and F ) NDN-treated (n=11) ranibizumab for three days and the cell index was measured continuously. Cell index values were normalized and analyzed as described in Material and Methods. Means ± standard deviations are shown in ( C – E ), means only in ( F ). Ranibizumab efficiently prevented VEGF-A 165 -induced decline of cell index values which was not changed by its passage either through a SHN or the NDN.
Ecgm Mv, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ecgm mv/product/PromoCell
Average 96 stars, based on 1 article reviews
ecgm mv - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
cell culture medium  (PromoCell)
97
PromoCell cell culture medium
Passage of ranibizumab through the NDN or SHN did not change its typical characteristics. After incubation of VEGF-A 165 with ( A ) untreated ranibizumab or ( B ) ranibizumab repeatedly passed through a needle, free growth factor was determined by ELISA. Data from independent experiments were pooled and analyzed as described in Material and Methods, and are shown as scatter plots with means ± standard deviations. *p<0.05, **p<0.01, ***p<0.001, ****) p<0.0001; only statistically significant differences are shown. All measured concentrations of free VEGF-A were very low. ( C – F ) Confluent monolayers of retinal <t>endothelial</t> cells (iBREC) were exposed to vehicle (n=6), VEGF-A 165 (n=8), the growth factor plus ( C and F ) untreated (n=8), ( D and F ) SHN-treated (n=12) or ( E and F ) NDN-treated (n=11) ranibizumab for three days and the cell index was measured continuously. Cell index values were normalized and analyzed as described in Material and Methods. Means ± standard deviations are shown in ( C – E ), means only in ( F ). Ranibizumab efficiently prevented VEGF-A 165 -induced decline of cell index values which was not changed by its passage either through a SHN or the NDN.
Cell Culture Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell culture medium/product/PromoCell
Average 97 stars, based on 1 article reviews
cell culture medium - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier

Image Search Results


Passage of ranibizumab through the NDN or SHN did not change its typical characteristics. After incubation of VEGF-A 165 with ( A ) untreated ranibizumab or ( B ) ranibizumab repeatedly passed through a needle, free growth factor was determined by ELISA. Data from independent experiments were pooled and analyzed as described in Material and Methods, and are shown as scatter plots with means ± standard deviations. *p<0.05, **p<0.01, ***p<0.001, ****) p<0.0001; only statistically significant differences are shown. All measured concentrations of free VEGF-A were very low. ( C – F ) Confluent monolayers of retinal endothelial cells (iBREC) were exposed to vehicle (n=6), VEGF-A 165 (n=8), the growth factor plus ( C and F ) untreated (n=8), ( D and F ) SHN-treated (n=12) or ( E and F ) NDN-treated (n=11) ranibizumab for three days and the cell index was measured continuously. Cell index values were normalized and analyzed as described in Material and Methods. Means ± standard deviations are shown in ( C – E ), means only in ( F ). Ranibizumab efficiently prevented VEGF-A 165 -induced decline of cell index values which was not changed by its passage either through a SHN or the NDN.

Journal: Clinical Ophthalmology (Auckland, N.Z.)

Article Title: Novel Needle for Intravitreal Injections Does Not Affect Biological Activity of Anti-VEGF Drugs

doi: 10.2147/OPTH.S557508

Figure Lengend Snippet: Passage of ranibizumab through the NDN or SHN did not change its typical characteristics. After incubation of VEGF-A 165 with ( A ) untreated ranibizumab or ( B ) ranibizumab repeatedly passed through a needle, free growth factor was determined by ELISA. Data from independent experiments were pooled and analyzed as described in Material and Methods, and are shown as scatter plots with means ± standard deviations. *p<0.05, **p<0.01, ***p<0.001, ****) p<0.0001; only statistically significant differences are shown. All measured concentrations of free VEGF-A were very low. ( C – F ) Confluent monolayers of retinal endothelial cells (iBREC) were exposed to vehicle (n=6), VEGF-A 165 (n=8), the growth factor plus ( C and F ) untreated (n=8), ( D and F ) SHN-treated (n=12) or ( E and F ) NDN-treated (n=11) ranibizumab for three days and the cell index was measured continuously. Cell index values were normalized and analyzed as described in Material and Methods. Means ± standard deviations are shown in ( C – E ), means only in ( F ). Ranibizumab efficiently prevented VEGF-A 165 -induced decline of cell index values which was not changed by its passage either through a SHN or the NDN.

Article Snippet: Briefly, cells were cultured in Endothelial Cell Growth Medium MV (ECGM; # C22120 , PromoCell, Heidelberg, Germany) until a confluent cell monolayer was reached three days later, indicated by a constantly high cell index (CI ~ 20).

Techniques: Incubation, Enzyme-linked Immunosorbent Assay